Bill119th CongressFiled Feb 6, 2025Health
H.R. 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it does
A plain-language summary from the Congressional Research Service isn’t available yet for this bill. CRS summaries are typically posted within a few weeks of introduction.
What just happenedFeb 6, 2025
Referred to the House Committee on Energy and Commerce.
Who’s behind it
Rep. Budzinski, Nikki [D-IL-13](D-IL)Sponsor
1committees3actions2subjects
- Introduced in HouseFeb 6, 2025
- Feb 6, 2025IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Feb 6, 2025IntroReferralIntro-H
Introduced in House
- Feb 6, 2025IntroReferral1000
Introduced in House